2021.05.13IR

Revised Consolidated Financial Report for the First Quarter 2021

2021.05.10IR

Consolidated Financial Report for the First Quarter 2021

2021.04.12IR

AnGes’ Phase 1b Trial Demonstrates Safety and Preliminary, Sustained Efficacy 12 Months After a Single Injection of NF-kappa B Oligo DNA Decoy in Subjects with Chronic Discogenic Low Back Pain

2021.03.25IR

COVID-19 Treatment AV-001: Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy

2021.03.18IR

AV-001: Co-development product by Vasomune Therapeutics and AnGes -Vasomune is Pleased to Announce the Government of Canada’s Investment in AV-001 Targeting COVID-19-

Learn more